Cargando…
Development and internal validation of multivariable prediction models for biochemical failure after MRI-guided focal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer
BACKGROUND AND PURPOSE: Magnetic resonance-guided focal salvage high-dose-rate brachytherapy (FS-HDR-BT) for radiorecurrent prostate cancer (PCa) shows low toxicity rates. However, biochemical failure (BF) after treatment occurs frequently. We developed two prediction models for BF (Phoenix definiti...
Autores principales: | Willigenburg, Thomas, van Son, Marieke J., van de Pol, Sandrine M.G., Eppinga, Wietse S.C., Lagendijk, Jan J.W., de Boer, Hans C.J., Moerland, Marinus A., van der Voort van Zyp, Jochem R.N., Peters, Max |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8261471/ https://www.ncbi.nlm.nih.gov/pubmed/34278009 http://dx.doi.org/10.1016/j.ctro.2021.06.005 |
Ejemplares similares
-
Determining the safety of ultrafocal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer: A toxicity assessment of 150 patients
por: van Son, Marieke, et al.
Publicado: (2020) -
Focal salvage treatment for radiorecurrent prostate cancer: A magnetic resonance-guided stereotactic body radiotherapy versus high-dose-rate brachytherapy planning study
por: Willigenburg, Thomas, et al.
Publicado: (2020) -
Focal Salvage Treatment of Radiorecurrent Prostate Cancer: A Narrative Review of Current Strategies and Future Perspectives
por: van Son, Marieke, et al.
Publicado: (2018) -
Second salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer
por: Maenhout, Metha, et al.
Publicado: (2017) -
Health-related quality of life after ultrafocal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer: reporting the patient’s perspective
por: van Son, Marieke, et al.
Publicado: (2020)